表紙
市場調查報告書
商品編碼
958713

SPECT(單一光子輻射斷層攝影)的全球市場

Single Photon Emission Computed Tomography (SPECT)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 469 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球SPECT(單一光子輻射斷層攝影)的市場規模在分析期間(2020年∼2027年)預計將以4.8%的年複合成長率增長,從2020年的13億美元到2027年達到18億美元。本報告分析市場區隔之一的循環系統部門在分析期間結束前預測將以5.6%的年率增長,達到7億6,270萬美元。

本報告提供全球SPECT(單一光子輻射斷層攝影)市場的相關調查,提供市場佔有率,趨勢和預測,成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Bruker Corporation
  • Digirad Corporation
  • Esaote SpA
  • GE Healthcare
  • Invicro, LLC
  • Mediso Medical Imaging Systems
  • MR Solutions Ltd.
  • Philips Healthcare
  • Siemens Healthineers
  • Trifoil Imaging, Inc.

目錄

I. 簡介,調查手法,調查範圍

II. 摘要整理

  • 市場概要
    • Covid-19的影響和即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
  • 主要企業
  • 趨勢與成長要素
  • 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:47公司
目錄
Product Code: MCP14973

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass Research Platform

» Complimentary updates for one year

Global Single Photon Emission Computed Tomography (SPECT) Market to Reach $2.5 Billion by 2026

SPECT imaging system is a type of nuclear imaging equipment. SPECT is used to evaluate disease processes that are based on metabolic and functional information of cells and organs. Lately, enhancing the diagnostic capability of various equipment in organic-specific or dual-modality systems has become very essential, which is expected to augment the market growth during the forecast period. It is a non-invasive, nuclear medicine based imaging technique that uses gamma rays for providing 2D and 3D information about various internal organs. Functioning of internal organs can be analyzed with greater assurance and accuracy with SPECT imaging. SPECT can offer 2D and 3D images of organs and additionally show how they work for instance, brain activity and pumping of blood by the heart. The nuclear medicine imaging method employs tracers or radioactive substances called probes and a specialized camera for detecting the radioactivity and for producing images. SPECT scanners can be useful in the diagnosis of strokes, seizures, and Alzheimer`s among other conditions. Heart related problems like artery blockages, heart attacks and chest pains can also be analyzed with greater precision. SPECT scanners produce 2D as well as 3D images. For higher quality results however, proper calibration of the systems as well as operation are necessary.

Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2026, growing at a CAGR of 6.8% over the analysis period. Standalone, one of the segments analyzed in the report, is projected to grow at a 6.2% CAGR to reach US$1.4 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybrid segment is readjusted to a revised 7.5% CAGR for the next 7-year period. This segment currently accounts for a 43.8% share of the global Single Photon Emission Computed Tomography (SPECT) market.

The U.S. Market is Estimated at $646.1 Million in 2021, While China is Forecast to Reach $274.4 Million by 2026

The Single Photon Emission Computed Tomography (SPECT) market in the U.S. is estimated at US$646.1 Million in the year 2021. The country currently accounts for a 36.07% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$274.4 Million in the year 2026 trailing a CAGR of 9.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR while Rest of European market (as defined in the study) will reach US$298.9 Million by the close of the analysis period.

The market is driven primarily by the booming healthcare industry. Increasing prevalence of lifestyle-induced disorders and growing elderly population also promote market growth. Furthermore, over the years, the growing trend of dual modality and organ specific systems greatly helped in increasing SPECT equipment`s diagnostic capabilities. Another factor promoting market growth is the rising prevalence of coronary artery diseases. Demand is also growing for hybrid SPECT imaging systems lately. Other growth promoting factors include increased research in the areas of radiopharmaceuticals development and growing awareness about the many benefits of the testing type over other imaging techniques among people. Continued technological sophistications being achieved in system designing and development of novel radiotracers also promote market growth. However, stringent regulations governing use of the systems hold potential to hamper anticipated market growth. The imaging systems are also highly expensive. High reagent costs, sensitivity of the reagents to storage conditions, and side effects arising from use of radiopharmaceuticals also act as market growth restricting factors. There are also a few alternatives to SPECT for instance, scintigraphy, increasing popularity of which can limit market growth.

Gallium-67 is estimated to witness a high CAGR in the SPECT market. Gallium-67 is a radioisotope used in diagnosing inflammation, acute and chronic infections, and tumors. It is also used as a bone imaging agent. Hybrid imaging using Gallium-67 SPECT/CT helps in exactly localizing the tumors. It is estimated that by 2040, new cancer cases would increase to 27.5 million and the cancer burden is expected to grow by 70% globally in the coming 20 years.

Select Competitors (Total 45 Featured) -

  • Beijing Hamamatsu Photon Techniques Inc.
  • Bracco Imaging
  • Bruker Corporation
  • Cadinal Health Inc
  • Curium
  • DDD-Diagnostic A/S
  • Digirad Corporation
  • GE Healthcare (GE Company)
  • Koninklijke Philips N.V.
  • Mediso Ltd.
  • MiE America, Inc.
  • Novartis AG
  • Siemens Healthcare
  • Spectrum Dynamics Medical

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • SPECT in Diagnosing Pulmonary Embolism amid COVID-19 Pandemic
    • Single Photon Emission Computed Tomography (SPECT) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • A Prelude to Single-Photon Emission Computed Tomography (SPECT)
    • Prominent Indications for SPECT Scanning
    • Global SPECT Market to Witness Steady Growth over the Coming Years
    • Hybrid SPECT Systems Witness Increased Demand.
    • Cardiology Dominates the Application for SPECT
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • United States Dominates the Global SPECT Market, Asia-Pacific to Register Faster Growth
    • Competition
    • Recent Market Activity
  • WORLD BRANDS
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • SPECT Dominates the Nuclear Medicine Market
    • Global Radiopharmaceuticals Market Revenues in U$ Million for Years 2019, 2021, 2023 & 2025
    • Worldwide Installed Base of Nuclear Imaging Equipment by Modality (2019): Percentage Breakdown of Units Installed for PET and SPECT
    • SPECT Systems with Anger Camera Remain the Dominant Type
    • Rapidly Growing Geriatric Population and the Rise in Associated Diseases Catalyze Growth
    • Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020, 2025, 2030 & 2050
    • Rising Incidence of Chronic Diseases Propels the Demand for Medical Imaging
    • Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • Oncology Diagnostic Imaging to Witness Rapid Growth
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2018
    • Growing Emphasis on Early Diagnosis is a Driving Factor for Diagnostic Imaging
    • Rise in Healthcare Expenditure to Drive Growth
    • Elderly Healthcare Expenditure as a % of GDP
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • SPECT Systems with Anger Camera Remain the Dominant Type
    • Growing Demand for Dual-Modality and Organ-Specific Systems Augurs Well
    • Growing Adoption of Hybrid Diagnostic Imaging Modalities
  • SPECT-CT
    • Commercialization of SPECT/CT Systems with Enhanced Features Surges
    • SPECT Combined with CT and PET, the new Rage
    • Integration of X-ray CT Enhances SPECT Capabilities
    • Proper Selection of Isotopes Highly Important for SPECT
    • Sustained Opportunities for Ga-67 SPECT Systems
    • PET Eclipses SPECT in Cardiovascular Imaging
    • Personalized Medicine Drives SPECT Market
    • Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
    • Rise in Incidence of Neurological Disorders to Drive Growth
    • Technological Advancements in the Recent Past
    • Yale University Research Team Attempts to use Deep Learning for Estimating Attenuation Maps using SPECT Emission Data (2020)
    • Siemens Healthineers Debuts New Version of c.cam Cardiac SPECT System
    • NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals
    • Technological Advancements in Cardiac SPECT (2019)
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Standalone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Standalone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 4: World Recent Past, Current & Future Analysis for Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Hybrid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Hybrid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 7: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 13: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 19: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 22: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 25: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 28: World Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
    • TABLE 31: USA Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 34: USA Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 37: USA Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 43: Canada Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • JAPAN
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
    • TABLE 49: Japan Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 55: Japan Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • CHINA
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
    • TABLE 58: China Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 61: China Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 64: China Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • EUROPE
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
    • TABLE 67: Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 73: Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
  • FRANCE
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
    • TABLE 79: France Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 82: France Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 85: France Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: France 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • GERMANY
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Germany Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Germany 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 91: Germany Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Germany 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • ITALY
    • TABLE 97: Italy Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Italy Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Italy 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 103: Italy Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Italy 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • UNITED KINGDOM
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
    • TABLE 106: UK Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: UK Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: UK 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 109: UK Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 112: UK Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: UK 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • SPAIN
    • TABLE 115: Spain Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Spain Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: Spain 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 118: Spain Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Spain Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: Spain 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 121: Spain Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Spain Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Spain 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • RUSSIA
    • TABLE 124: Russia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Russia Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Russia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 127: Russia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Russia Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Russia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 130: Russia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Russia Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Russia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF EUROPE
    • TABLE 133: Rest of Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 136: Rest of Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 139: Rest of Europe Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of Europe Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Rest of Europe 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • ASIA-PACIFIC
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
    • TABLE 142: Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 145: Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 148: Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
    • TABLE 151: Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 152: Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
  • AUSTRALIA
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
    • TABLE 154: Australia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Australia Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Australia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 157: Australia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Australia Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Australia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 160: Australia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Australia Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Australia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • INDIA
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
    • TABLE 163: India Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: India Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: India 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 166: India Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: India Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: India 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 169: India Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: India Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: India 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • SOUTH KOREA
    • TABLE 172: South Korea Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: South Korea Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: South Korea 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 175: South Korea Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: South Korea Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: South Korea 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 178: South Korea Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: South Korea Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: South Korea 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 181: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Rest of Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Rest of Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 184: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 187: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Asia-Pacific Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Asia-Pacific 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • LATIN AMERICA
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
    • TABLE 190: Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 193: Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 196: Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
    • TABLE 199: Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 200: Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
  • ARGENTINA
    • TABLE 202: Argentina Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Argentina Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Argentina 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 205: Argentina Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Argentina Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Argentina 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 208: Argentina Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Argentina Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 210: Argentina 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • BRAZIL
    • TABLE 211: Brazil Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Brazil Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 213: Brazil 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 214: Brazil Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Brazil Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 216: Brazil 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 217: Brazil Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Brazil Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 219: Brazil 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • MEXICO
    • TABLE 220: Mexico Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Mexico Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 222: Mexico 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 223: Mexico Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Mexico Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 225: Mexico 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 226: Mexico Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Mexico Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 228: Mexico 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF LATIN AMERICA
    • TABLE 229: Rest of Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Rest of Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 231: Rest of Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 232: Rest of Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Rest of Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 234: Rest of Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 235: Rest of Latin America Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Rest of Latin America Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 237: Rest of Latin America 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • MIDDLE EAST
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
    • TABLE 238: Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 240: Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 241: Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 243: Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 244: Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 246: Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
    • TABLE 247: Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 248: Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 249: Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
  • IRAN
    • TABLE 250: Iran Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Iran Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 252: Iran 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 253: Iran Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Iran Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 255: Iran 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 256: Iran Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Iran Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 258: Iran 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • ISRAEL
    • TABLE 259: Israel Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Israel Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 261: Israel 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 262: Israel Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Israel Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 264: Israel 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 265: Israel Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Israel Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 267: Israel 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • SAUDI ARABIA
    • TABLE 268: Saudi Arabia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Saudi Arabia Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 270: Saudi Arabia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 271: Saudi Arabia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Saudi Arabia Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 273: Saudi Arabia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 274: Saudi Arabia Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Saudi Arabia Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 276: Saudi Arabia 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 277: UAE Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 278: UAE Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 279: UAE 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 280: UAE Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 281: UAE Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 282: UAE 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 283: UAE Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 284: UAE Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 285: UAE 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • REST OF MIDDLE EAST
    • TABLE 286: Rest of Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Rest of Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 288: Rest of Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 289: Rest of Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Rest of Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 291: Rest of Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 292: Rest of Middle East Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Rest of Middle East Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 294: Rest of Middle East 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027
  • AFRICA
    • Single Photon Emission Computed Tomography (SPECT) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
    • TABLE 295: Africa Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Africa Historic Review for Single Photon Emission Computed Tomography (SPECT) by Product Type - Standalone and Hybrid Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 297: Africa 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Product Type - Percentage Breakdown of Value Sales for Standalone and Hybrid for the Years 2012, 2021 & 2027
    • TABLE 298: Africa Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Africa Historic Review for Single Photon Emission Computed Tomography (SPECT) by Application - Cardiology, Oncology, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 300: Africa 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by Application - Percentage Breakdown of Value Sales for Cardiology, Oncology, Neurology and Other Applications for the Years 2012, 2021 & 2027
    • TABLE 301: Africa Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Africa Historic Review for Single Photon Emission Computed Tomography (SPECT) by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 303: Africa 15-Year Perspective for Single Photon Emission Computed Tomography (SPECT) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 45